Glutamine-metabolizing enzymes

Glutamine-metabolizing enzymes are a diverse group of proteins that regulate the synthesis, catabolism, and utilization of glutamine, the most abundant amino acid in human plasma (Source: NIH). Key members include glutaminase (GLS), which initiates glutaminolysis by converting glutamine to glutamate, and glutamine synthetase (GLUL), which catalyzes the de novo synthesis of glutamine from glutamate and ammonia (Source: PubMed). These enzymes are frequently hijacked by cancer cells to support increased bioenergetic and biosynthetic demands, a phenomenon known as glutamine addiction (Source: Nature Reviews Cancer). By providing intermediates for the tricarboxylic acid (TCA) cycle and precursors for nucleotide and glutathione synthesis, these enzymes facilitate rapid tumor growth and redox balance (Source: Cell Metabolism). Therapeutic targeting of this pathway involves selective inhibitors like telaglenastat (CB-839) or broad glutamine antagonists like DRP-104 (Source: Journal of Clinical Medicine). However, clinical development faces challenges such as metabolic plasticity, where cells bypass inhibited pathways, and potential neurotoxicity due to the role of glutamate as a major excitatory neurotransmitter (Source: Frontiers in Oncology). Additionally, these enzymes play roles in other conditions such as neurodegeneration and metabolic disorders, where glutamate/glutamine balance is disrupted (Source: StatPearls). Research continues to explore combination therapies to overcome resistance and improve the therapeutic window of these agents (Source: ClinicalTrials.gov).

Other names

Glutaminolysis enzymesGlutamine metabolic enzymesGlutamine metabolism enzymes

Inhibition of glutaminase (GLS) to block the conversion of glutamine to glutamate, inhibition of glutamine synthetase (GS) to prevent de novo glutamine synthesis, competitive antagonism of glutamine-binding sites across multiple enzymes, and allosteric inhibition of glutamate dehydrogenase (GDH).